Stocks Health care RNA
NASDAQ · Health careAtrium Therapeutics, Inc. (RNA)
At June 30, 2026 it held $72.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Atrium Therapeutics, Inc.
- Net worth
- Atrium Therapeutics, Inc. has a market value (market cap) of $140.8M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Atrium Therapeutics, Inc. does
Atrium Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNA.
Earnings: every quarter and the next report date
Latest SEC filings
What Atrium Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026
- October 27, 2026Other event 8-K
- October 9, 2026Other event 8-K/A
- October 8, 2026Material agreement8-KAtrium Therapeutics agreed to raise approximately $50 million through a private placement of common stock and pre-funded warrants.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 22% to $3M versus the same quarter last year; diluted EPS -$1.18 versus -$0.75.
- August 13, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Atrium Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 8 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Hoyos Rocio MartinChief Strategy Officer | Shares withheld for tax | 8,320 | $74.5K |
| September 18, 2026 | Winslow Brendan R.Chief Financial Officer | Shares withheld for tax | 6,742 | $60.3K |
| September 18, 2026 | Gallagher Kathleen P.See Remarks, Director | Shares withheld for tax | 11,632 | $104.1K |
| September 18, 2026 | Kenney StephanieSee Remarks | Shares withheld for tax | 2,375 | $21.3K |
| September 18, 2026 | Boyce SarahDirector | Shares withheld for tax | 126,418 | $1.1M |
| September 18, 2026 | Flanagan W. MichaelDirector | Shares withheld for tax | 22,812 | $204.2K |
| September 18, 2026 | Hughes Steven GeorgeChief Medical Officer | Shares withheld for tax | 21,459 | $192.1K |
| September 18, 2026 | Younis HusamChief Scientific Officer | Shares withheld for tax | 11,216 | $100.4K |
Who owns RNA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Sessa Capital IM, L.P.13G, passive with 1 related filers | 8.8% | August 14, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 8.6% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 155 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Sessa Capital IM, L.P. | 1,500,000 | +948,609 |
| BlackRock, Inc. | 1,447,476 | +242,185 |
| Crcm LP | 1,283,078 | new |
| Vanguard Capital Management LLC | 730,831 | +103,962 |
| TIG Advisors, LLC | 561,533 | -46,019 |
| Arbiter Partners Capital Management LLC | 522,576 | +292,576 |
| Cantor Fitzgerald, L. P. | 513,834 | +278,197 |
| Geode Capital Management, LLC | 386,929 | +67,098 |
| Two Sigma Investments, LP | 345,481 | +166,921 |
| Goldman Sachs Group Inc | 310,341 | -39,609 |
| 683 Capital Management, LLC | 300,000 | 0 |
| State Street Corp | 271,762 | +14,676 |
| Slotnik Capital, LLC | 237,637 | +56,692 |
| Weiss Asset Management LP | 219,730 | -20,971 |
| Millennium Management LLC | 200,559 | +9,700 |
| Schonfeld Strategic Advisors LLC | 199,158 | +36,399 |
| Aqr Capital Management LLC | 172,235 | new |
| Nexpoint Asset Management, L.P. | 150,025 | 0 |
| Polar Asset Management Partners Inc. | 150,000 | +80,000 |
| Squarepoint Ops LLC | 146,743 | -84,723 |
Insiders
8 insiders reported holding 491,734 shares in total, about $4M at the last price.
| Holder | Shares |
|---|---|
| Boyce SarahDirector | 138,668 |
| Gallagher Kathleen P.See Remarks, Director | 119,729 |
| Hughes Steven GeorgeChief Medical Officer | 51,638 |
| Younis HusamChief Scientific Officer | 41,441 |
| Hoyos Rocio MartinChief Strategy Officer | 38,340 |
| Winslow Brendan R.Chief Financial Officer | 36,859 |
| Kenney StephanieSee Remarks | 33,085 |
| Flanagan W. MichaelDirector | 31,974 |
Questions about RNA
What does Atrium Therapeutics, Inc. do?
Atrium Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as RNA. Its shares trade on NASDAQ under the ticker RNA.
What is Atrium Therapeutics, Inc.'s net worth?
Atrium Therapeutics, Inc. has a market value (market cap) of $140.8M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Atrium Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from November 2, 2026.
Similar companies
Compare RNA with
Follow RNA
Get an email when Atrium Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Atrium Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.